作为慢性脏疾病认知障碍的生物标志物,脂蛋白相关脂酶A2的升高是慢性脏疾病的生物标志物
Sujuan Feng1, Yanfeng Lin2, Rong Wang1
1Department of Nephrology, Affiliated Hospital 2 of Nantong University, Nantong, 226000, China.
International urology and nephrology
|April 1, 2025
概括
升高的脂蛋白相关脂酶A2 (Lp-PLA2) 水平与慢性病 (CKD) 患者的认知障碍 (CI) 有关. 较高的Lp-PLA2表明在这个人群中发展CI的独立风险因素.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 神经学 神经学
- 生物化学 生化学
背景情况:
- 慢性病 (CKD) 与认知障碍 (CI) 的风险增加有关.
- 关联CKD和CI的潜在机制需要进一步阐明.
- 脂蛋白相关脂酶A2 (Lp-PLA2) 是一种炎症标记物,与心血管疾病和潜在的神经退行过程有关.
研究的目的:
- 调查血清Lp-PLA2水平与CKD患者中CI的存在之间的关联.
- 确定Lp-PLA2作为CKD患者群体中CI的潜在风险因素.
主要方法:
- 一组125名CKD患者被分为有CI和没有CI的组.
- 用蒙特利尔认知评估 (MoCA) 尺度测量血清Lp-PLA2水平并与认知功能相关联.
- 使用多变量逻辑回归和ROC曲线分析来评估风险因素和诊断效用.
主要成果:
- 与没有CI的患者相比,CI患者的血清Lp-PLA2水平显著更高 (P<0.05).
- 血清Lp-PLA2水平与CKD患者的CI独立相关 (OR = 0.988,P < 0.001).
- 232 ng/mL的Lp-PLA2截止值显示了该队列中CI的良好诊断准确性 (AUC = 0.849).
结论:
- 血清Lp-PLA2水平升高是慢性病患者认知障碍的独立危险因素.
- Lp-PLA2可以作为一种有价值的生物标志物,用于识别患有认知衰退风险更高的CKD患者.
相关概念视频
Factors Affecting Renal Clearance: Renal Impairment
30
Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
30
Blood Studies for Cardiovascular System III: Serum Lipid Profile
98
Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
98
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
37
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
37
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
85
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
85
Alzheimer's Disease: Overview
313
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
313


